Please ensure Javascript is enabled for purposes of website accessibility

Why Heat Biologics Stock Surged Today

By Joe Tenebruso – Aug 13, 2020 at 1:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Encouraging early results for the biotech's coronavirus vaccine have investors excited.

What happened

Shares of Heat Biologics (HTBX -1.09%) popped on Thursday after the biopharmaceutical company shared promising preclinical data for its COVID-19 vaccine. As of 1:30 p.m. EDT, Heat Biologics' stock was up 15% after rising as much as 23% earlier in the day. 

So what

Heat Biologics said data generated at the University of Miami Miller School of Medicine showed a "robust T cell driven immune response" to SARS-CoV-2, the virus that causes COVID-19. The biotech company said its experimental vaccine induced the expansion of CD8+ T cells that kill virus-infected cells, as well as CD4+ T cells that help to produce antibodies. Better still, the T cells released cytokines that boosted the anti-viral immune response, which Heat Biologics believes could play an important role in protecting against respiratory viruses.

"Specifically, we noted several important immune responses generated by the vaccine against SARS-CoV-2 after a single injection, including SARS-CoV-2 specific CD8+ and CD4+ T cells in the lungs and airways," University of Miami Professor Natasa Strbo said in a press release.

People are working in a laboratory.

Heat Biologics stock rose sharply on positive coronavirus vaccine data. Image source: Getty Images.

Now what

Heat Biologics CEO Jeff Wolf believes this robust T cell activity could set its vaccine candidate apart from others, while also potentially allowing it to be used alongside them. "Unlike most of these approaches that drive primarily an antibody response, our COVID-19 vaccine is designed to drive predominantly T cell immunity along with antibody responses and innate immunity," Wolf said in a press release. "As a result, we believe our vaccine has the potential to be used as either a stand-alone vaccine, or in combination with these other approaches to enhance efficacy."

Heat Biologics said it will publish the full details of its study in the coming weeks.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heat Biologics, Inc. Stock Quote
Heat Biologics, Inc.
HTBX
$1.81 (-1.09%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.